C3.ai announced today that CEO Tom Siebel would be stepping down and that the company was in the process of looking for its ...

These two companies are both leading the artificial intelligence charge, but one business stands out as superior.

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

What To Know: C3.ai said it initiated a search for a new CEO to replace Thomas Siebel, who is battling health issues. The ...

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...

Tempus AI has multiple layers of wins to demonstrate. In terms of financials, the cash buffers (including short term ...

Investing.com -- C3.ai (NYSE: AI) stock fell 4% after the Enterprise AI application software company announced it has initiated a search for a successor to replace founder and CEO Thomas M. Siebel.

To get a sense of who is truly in control of C3.ai, Inc. , it is important to understand the ownership structure of the business. We can see that institutions own the lion's share ...

This was the stock's second consecutive day of gains.

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...